TCM
CTIC

Tang Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Tang Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300,000
Closed -$1.8M – 127
2022
Q4 		$1.8M Hold
300,000
– – 0.26% 63
2022
Q3 		$1.75M Buy
+300,000
New +$1.87M 0.21% 73

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Tang Capital Management's CTIC Position: Q1 2023 in Review

Tang Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 300,000 shares — an estimated $1.8M sold.

Tang Capital Management first reported a position in CTIC in Q3 2022 and held it in 2 quarters. The position peaked at $1.8M in Q4 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

  • Tang Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
  • Tang Capital Management sold 300,000 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $1.8M.
  • Tang Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2022 and held it in 2 quarters.
  • Tang Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $1.8M in Q4 2022.
  • 133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on Tang Capital Management's 13F filing for Q1 2023, filed 15 May 2023.